Overview
Malakoplakia is a rare inflammatory disorder characterized by the proliferation of dysfunctional macrophages with intracytoplasmic inclusions known as Michaelis-Gutmann bodies, typically affecting the urinary tract but occasionally involving other organs including the stomach, testis, and kidneys 145.Diagnosis
Clinical Presentation: Often presents with nonspecific symptoms depending on the affected organ (e.g., hypercalcemia in renal involvement, testicular enlargement 23).
Microscopic Features: Histopathology reveals macrophages with PAS-positive granules and Michaelis-Gutmann bodies 14.
Immunohistochemistry: Positive for lysozyme in Michaelis-Gutmann bodies, confirming lysosomal origin 4.
Imaging and Laboratory Tests: May include imaging studies and laboratory tests to assess organ function and specific markers (e.g., hypercalcemia, vitamin D levels 1).Management
Steroids: High-dose corticosteroids (e.g., prednisolone) may be used to reduce inflammation and modulate immune response 4.
Supportive Care: Rehydration, electrolyte management (e.g., for hypercalcemia 1), and discontinuation of exacerbating factors (e.g., stopping cholecalciferol supplementation 1).
Specific Treatments: No specific antimicrobial therapy universally recommended; treatment may target underlying infection if identified 4.Special Populations
Elderly: Case reports indicate malakoplakia can occur in elderly patients, particularly affecting organs like the testis 23.
Comorbidities: Management may need to consider concurrent conditions such as hepatic necrosis, requiring careful monitoring and supportive care 4.Key Recommendations
Histopathological Confirmation: Definitive diagnosis requires histopathological examination showing characteristic macrophage infiltration and Michaelis-Gutmann bodies (Evidence: Moderate 4).
Initiate Corticosteroids: For confirmed cases, especially with significant inflammation, high-dose corticosteroids like prednisolone should be considered (Evidence: Weak 4).
Manage Hypercalcemia: In cases with hypercalcemia, discontinue vitamin D supplementation and implement rehydration therapy (Evidence: Weak 1).
Monitor and Supportive Care: Regular monitoring of organ function and supportive care tailored to specific symptoms and comorbidities (Evidence: Expert opinion).References
1 Chemouny JM, Sannier A, Hanouna G, Champion L, Vrtovsnik F, Daugas E. Malakoplakia as a cause of severe hypercalcemia through ectopic 25-hydroxyvitamin D3 1-alpha-hydroxylase expression: A case report. Medicine 2018. link
2 Kostakopoulos A, Giannakopoulos S, Demonakou M, Deliveliotis Ch. Malakoplakia of the testis. Case report. International urology and nephrology 1998. link
3 Kostakopoulos A, Giannakopoulos S, Demonakou M, Deliveliotis C. Malakoplakia of the testis. International urology and nephrology 1997. link
4 Nonomura A, Kono N, Takazakura E, Ohta G. Renal and prostatic malakoplakia associated with submassive hepatic necrosis. A case report with immunocytochemical, ultrastructural and X-ray analytical observations. Acta pathologica japonica 1986. link
5 Kleinman SZ, Robinson ND, Simon SA. Malakoplakia of testis. Urology 1983. link90510-1)